Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Simcere Pharmaceutical Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed locally advanced or metastatic solid tumors or histopathologically confirmed NHL
Relapsed/refractory solid tumor or relapsed/refractory NHL who have progressed during or after standard therapy or for which treatment is not tolerated, not suitable, not available.
At least one evaluable or measurable lesion (as defined in the protocol).
ECOG Performance Status 0 or 1.
Life expectancy ≥12 weeks.
Adequate organ function (as defined in the protocol).
Reproductive criteria (as defined in the protocol).
You may not be if
Any clinically significant gastrointestinal (GI) abnormalities that may alter absorption.
Major surgery, systemic anti-cancer therapy or investigational drug(s) within 4 weeks prior to study entry. Radiation therapy within 2 weeks prior to study entry.
Adverse reactions from previous anti-tumor therapy have not yet recovered to ≤ grade 1(excluding hair loss, peripheral neurotoxicity caused by chemotherapy have recovered to ≤ grade 2 ).
Autologous hematopoietic stem cell transplantation was performed within 9 months prior to the first dose.
History of a second malignancy within 2 years (as defined in the protocol).
Active uncontrolled or symptomatic lung disease (as defined in the protocol).
Intracranial hypertension or active uncontrolled or symptomatic CNS metastases.
Known or suspected hypersensitivity to study medications.
Known active uncontrolled or symptomatic CNS metastases.
The investigator determined that the patient should not participate in the study.
Known mental illness or substance abuse that may disrupt therapy.
Clinically significant cardiac abnormalities (as defined in the protocol).
Gestating or Lactating women.
Pleural effusion, pericardial effusion or ascites that need diuretics or draining within 2 weeks prior to first dose.
The patient is currently using a drug known to be a strong inhibitor or inducer of CYP3A4.
Clareo Health | A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
